Together, these results identified TRAIL+ myeloid cells as a critical mechanism in the resolution of pulmonary fibrosis, and strategies directed at promoting its function might have therapeutic potential in IPF. This evidence concerns the gene TNFSF10 and idiopathic pulmonary fibrosis.